Effect of Gastrointestinal Manifestations on Quality of Life in 87 Consecutive Patients with Systemic Sclerosis
Effect of Gastrointestinal Manifestations on Quality of Life in 87 Consecutive Patients with Systemic Sclerosis
复制标题
DOI：
10.3899/jrheum.110826
复制
发表时间：
2012-05-01
影响因子：
3.9
通讯作者：
Lee, Peter
中科院分区：
文献类型：
--
作者：
Omair, Mohammed A.;Lee, Peter
Objective.目的探讨系统性硬化症（SSc）患者胃肠道（GI）表现对生活质量的影响。加州大学，洛杉矶硬皮病临床试验联盟胃肠道2问卷由87名在单一中心参加硬皮病诊所的连续SSc患者完成。他们的临床特点和目前的治疗方法进行了记录，100例风湿性疾病的其他SSc作为对照。比较SSc和对照组之间以及SSc亚组之间的个体评分。87例患者中，76例（90%）为女性。中位年龄为55岁，病程为105个月。33例（38%）为弥漫性SSc，54例（62%）为局限性SSc。SSc患者在所有领域的得分均高于对照组（p < 0.05）。对单个问卷组成部分有积极应答的患者人数如下：任何GI症状86例（99%）、反流77例（89%）、腹胀73例（84%）、污物19例（22%）、腹泻44例（51%）、便秘51例（59%）、健康状况43例（49%）和社交43例（49%）。弥漫型和局限型患者的评分无差异。钙通道阻滞剂的使用没有显著增加便秘评分（p = 0.99）。对反流、腹胀、腹泻和便秘领域反应积极的患者在幸福感和社会领域的得分较低。胃肠道表现，特别是大便失禁（影响22%的患者），对SSc患者的生活质量有负面影响。SSc疾病亚型之间无差异。（2012年4月1日首次发布; J Rheumol 2012;39：992-6; doi：10.3899/jrheum.110826）
Objective. To assess the effect of gastrointestinal (GI) manifestation on the quality of life in patients with systemic sclerosis (SSc).Methods. The University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2 questionnaire was completed by 87 consecutive patients with SSc attending the scleroderma clinic at a single center. Their clinical features and current therapies were recorded; 100 patients with rheumatologic disorders other than SSc were used as controls. Individual scores were compared between SSc and controls, and between SSc subgroups.Results. Of 87 patients, 76 (90%) were women. Median age was 55 years and disease duration 105 months. Thirty-three (38%) had diffuse and 54 (62%) had limited SSc. Patients with SSc had a higher score than controls in all domains (p < 0.05). Numbers of patients who responded positively to individual questionnaire components are as follows: any GI symptom 86 (99%), reflux 77 (89%), distension 73 (84%), soilage 19(22%), diarrhea 44(51%), constipation 51(59%), well-being 43 (49%), and social 43 (49%). There was no difference between the scores of patients with diffuse and limited disease subtypes. The use of calcium channel blockers did not significantly increase the constipation score (p = 0.99). Patients who responded positively to the reflux, distension, diarrhea, and constipation domains had lower scores in the well-being and social domains.Conclusion. GI manifestations, especially fecal incontinence (affecting 22% of patients), have a negative influence on the quality of life of patients with SSc. There was no difference between SSc disease subtypes. (First Release April 1 2012; J Rheumatol 2012;39:992-6; doi:10.3899/jrheum.110826)